Australia · Delayed Price · Currency is AUD Emyria Company Description
Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia.
The company operates through Clinical Services, Clinical Services, and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression.
The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name.
It has a collaboration partnership with the University of Western Australia to support the expand Emyria’s MDMA analogue drug development program.
The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020.
Emyria Limited was incorporated in 2018 and is headquartered in Leederville, Australia.
| Country | Australia |
| Founded | 2018 |
| Industry | Health Information Services |
| Sector | Healthcare |
| CEO | Michael Winlo |
Contact Details
Address: D2, 661 Newcastle Street Leederville, 6007 Australia | |
| Phone | 61 8 6559 2800 |
| Website | emyria.com |
Stock Details
| Ticker Symbol | EMD |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000073645 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gregory Hutchinson | Executive Chairman |
| Dr. Michael Winlo | Chief Scientific Officer and Executive Director |
| Joseph Daniel Ohayon ACA, MBA Intl Bus. | Chief Financial Officer |
| Dr. Alistair Vickery | Executive Medical Director and Director |
| Tracie Ernenwein | Head of Research and Drug Development |
| Mary-Ann Rennie | Head of Corporate Operations |
| Susan Patricia Park A.C.A., A.C.I.S., ACSA, AGIA, B.Com., C.A., F Fin | Company Secretary |